Good morning :)
Place Order
Add to Watchlist

Divi's Laboratories Ltd

DIVISLAB

Divi's Laboratories Ltd

DIVISLAB
Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹1,57,949 cr, stock is ranked 54
Low RiskStock is 1.81x as volatile as Nifty
5,949.850.17% (-10.10)
5,949.850.17% (-10.10)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹1,57,949 cr, stock is ranked 54
Low RiskStock is 1.81x as volatile as Nifty

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹1,57,949 cr, stock is ranked 54
Low RiskStock is 1.81x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
86.0311.640.50%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.356.540.51%

Forecast & Ratings

Detailed Forecast 
39%
Analysts have suggested that investors can buy this stock

from 23 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.91%, vs industry avg of 4.51%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 41.61% to 46.53%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 3.41%, vs industry avg of 5.9%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue3,873.804,139.234,004.935,101.895,584.057,031.969,073.708,112.008,184.008,973.00
Raw Materialssubtract1,478.711,608.361,567.942,169.722,256.992,455.403,552.073,087.003,300.006,056.00
Power & Fuel Costsubtract180.34198.80228.73248.78280.73319.15392.33496.00477.00
Employee Costsubtract361.19499.90456.06542.27621.05825.76946.16975.001,094.00
Selling & Administrative Expensessubtract134.18154.26200.48175.70228.23287.84345.20393.00358.00
Operating & Other expensessubtract203.61155.88175.53-63.23184.21220.08-159.07447.00410.00
Depreciation/Amortizationsubtract118.18123.33142.49168.90186.24255.59311.51343.00378.00386.00
Interest & Other Itemssubtract4.743.362.374.687.142.102.002.004.003.00
Taxes & Other Itemssubtract267.06334.92354.32502.33442.92681.75723.05545.00563.00692.00
EPS42.4139.9533.0450.9651.8574.75111.5268.7160.2769.16
DPS10.0010.0010.0016.0016.0020.0030.0030.0030.0030.00
Payout ratio0.240.250.300.310.310.270.270.440.500.43

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Divi's Laboratories Ltd98.7211.640.50%
Syngene International Ltd70.688.470.14%
Aarti Pharmalabs Ltd27.523.400.46%
Dishman Carbogen Amcis Ltd-19.360.53

Price Comparison

Compare DIVISLAB with any stock or ETF
Compare DIVISLAB with any stock or ETF
DIVISLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.09%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding51.89%11.92%9.14%17.25%9.80%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep14.70%14.60%14.86%14.68%16.16%17.25%

Mutual Funds Holding Trend

Decreased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.18%

Top 5 Mutual Funds holding Divi's Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI Equity Hybrid Fund - Growth - Direct Plan

Growth
1.9495%4.11%0.75%7/96 (+2)
SBI Focused Equity Fund - Growth - Direct Plan

Growth
1.0479%4.55%0.00%6/34 (+2)
SBI Blue Chip Fund - Growth - Direct Plan

Growth
1.0186%3.19%0.56%9/57 (+1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

DIVISLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.50%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.04 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 2, 2024

Final
Final | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Aug 2, 2024

Cash Dividend

Ex DateEx DateAug 11, 2023

Final
Final | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Aug 11, 2023

Cash Dividend

Ex DateEx DateAug 11, 2022

Final
Final | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Aug 11, 2022

Cash Dividend

Ex DateEx DateAug 17, 2021

Final
Final | Div/Share: ₹20.00

Dividend/Share

20.00

Ex DateEx Date

Aug 17, 2021

Cash Dividend

Ex DateEx DateFeb 25, 2020

Interim
Interim | Div/Share: ₹16.00

Dividend/Share

16.00

Ex DateEx Date

Feb 25, 2020

News & Opinions
Spotlight
Divi's Labs PAT soars 47% YoY to Rs 510 crore in Q2

Total income grew by 22.51% year on year (YoY) to Rs 2,444 crore in the quarter ended 30 September 2024. Profit before tax for the quarter was at Rs 722 crore, up 53.94% from Rs 469 crore reported in the same period a year ago. Total expenses stood at Rs 1,722 crore in second quarter of FY25, up 12.84% on YoY basis. Cost of material consumed was at Rs 976 crore (up 37.27% YoY) and employee benefit expenses stood at Rs 304 crore (up 14.29% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 29 crore as against a gain of Rs 11 crore posted in Q2 FY24. On half yearly basis, the company's net profit climbed 33.52% to Rs 940 crore on 20.86% rise in revenue from operations to Rs 4,456 crore in H1 FY25 over H1 FY24. Forex gain for the six month period amounted to Rs 28 crore as against a gain of Rs 14 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Shares of Divi's Laboratories declined 0.34% to end at Rs 5,938.15 on Friday, 8 November 2024. Powered by Capital Market - Live

15 hours agoCapital Market - Live
Earnings
Divi's Laboratories consolidated net profit rises 46.55% in the September 2024 quarter

Net profit of Divi's Laboratories rose 46.55% to Rs 510.00 crore in the quarter ended September 2024 as against Rs 348.00 crore during the previous quarter ended September 2023. Sales rose 22.47% to Rs 2338.00 crore in the quarter ended September 2024 as against Rs 1909.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2338.001909.00 22 OPM %30.6225.09 - PBDT821.00564.00 46 PBT722.00469.00 54 NP510.00348.00 47 Powered by Capital Market - Live

16 hours agoCapital Market - Live
Corporate
Divis Laboratories declare Quarterly Result

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Divis Laboratories Ltd slips for fifth straight session

Divis Laboratories Ltd dropped for a fifth straight session today. The stock is quoting at Rs 5765.75, down 0.9% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 24547.8. The Sensex is at 80424.19, up 0.25%.Divis Laboratories Ltd has added around 7.25% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 1.88% in last one month and is currently quoting at 22828.2, down 0.33% on the day. The volume in the stock stood at 1.85 lakh shares today, compared to the daily average of 10.54 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 5799.15, down 0.66% on the day. Divis Laboratories Ltd jumped 67.44% in last one year as compared to a 28.37% rally in NIFTY and a 53.74% spurt in the Nifty Pharma index.The PE of the stock is 93.02 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
CARE Ratings reaffirms ratings of Divi's Labs with 'stable' outlook

The agency has also affirmed the company's short term rating at 'CARE A1+'. CARE Ratings stated that the ratings assigned to bank facilities of Divi's Laboratories continue to derive strength from the extensive experience of promoters and management team in the pharmaceutical industry, the company's established track record in Contract Research and Manufacturing Services (CRAMS) segment with reputed clientele, its strong research and development (R&D) capabilities and favourable industry outlook. Ratings factor in strong credit metrics characterised by sound capital structure, robust debt coverage indicators, and healthy liquidity maintained by the company. However, ratings are tempered by product and customer concentration risk despite reduced in FY24 as against FY23, working capital intensive operations, though funded entirely through internal accruals, exposure to the regulatory risk and forex fluctuation risk considering majority of the revenue being derived from exports. Stabilisation of total operating income (TOI) and attenuation in profitability margins in FY24 is primarily attributed to change in product mix, pricing pressure in generics segment, rise in raw material prices and freight costs. CARE Ratings expects improvement in TOI and margins in FY25 considering launch of new products, broadening of customer base, ease of raw material prices, improving demand, addition of capacity with operationalisation of Kakinada plant in second half of FY25, and increase in overall capacity utilisation. Divi's Laboratories is a pharmaceutical company engaged in generic API, custom synthesis, and nutraceuticals. The company is catering to therapeutic segments such as cardiovascular, anti-inflammatory, anti-cancer, central nervous system drugs among others. Divi's currently has seven manufacturing units (one in Kakinada under construction) and three R&D centres spread across Telangana and Andhra Pradesh. The scrip rose 0.42% to currently trade at Rs 5518.80 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Divis Laboratories receives affirmation in credit ratings for bank facilities

Divis Laboratories has received reaffirmation in credit ratings for bank facilities aggregating Rs 515 crore at CARE AA+; Stable/ CARE A1+ from CARE Ratings. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Divis Laboratories Ltd spurts 0.46%, rises for fifth straight session

Divis Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 5161.25, up 0.46% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 24855.65. The Sensex is at 81293.96, up 0.14%. Divis Laboratories Ltd has risen around 5.53% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 3.38% in last one month and is currently quoting at 23043.4, down 0.37% on the day. The volume in the stock stood at 2.18 lakh shares today, compared to the daily average of 4.9 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5176, up 0.74% on the day. Divis Laboratories Ltd is up 38.14% in last one year as compared to a 24.3% spurt in NIFTY and a 49.95% spurt in the Nifty Pharma index.The PE of the stock is 82.16 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Divis Laboratories Ltd up for third straight session

Divis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5151.7, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Divis Laboratories Ltd has risen around 6.71% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 1.87 lakh shares today, compared to the daily average of 4.92 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5159.45, up 0.89% on the day. Divis Laboratories Ltd is up 38.94% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 81.45 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Divis Laboratories Ltd rises for third straight session

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 4884.75, up 3.42% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24728.5. The Sensex is at 80764.15, down 0.05%. Divis Laboratories Ltd has gained around 7.72% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 9.29% in last one month and is currently quoting at 22374.25, up 0.83% on the day. The volume in the stock stood at 10.29 lakh shares today, compared to the daily average of 6.01 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 4881, up 3.44% on the day. Divis Laboratories Ltd is up 33.71% in last one year as compared to a 27.49% jump in NIFTY and a 47.43% jump in the Nifty Pharma index.The PE of the stock is 75.46 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live

RIL, Adani Ports, Divis Labs, TechM, Bajaj Auto: Half of Nifty shares trade at huge premium; stock picks

3 months agoBusiness Today